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ABSTRACT
Objective: The aim of the study was to study the cost of illness of uncomplicated and complicated type 2 diabetes mellitus.
Methods: The non-interventional retrospective study was carried out in K.S. Hegde Medical Academy. Annual laboratory costs, pharmacy cost, 
consultation charges, hospital bed charges, and surgical/intervention costs of 340 diabetic patients were obtained from the medical record section 
of the hospital. Patients were divided into six groups, uncomplicated, diabetic retinopathy (DR), nephropathy, neuropathy, diabetic foot (DF), and 
those with ischemic heart disease (IHD) and different costs were compared. Correlation of costs with duration of the study and glycemic control were 
studied.
Results: Uncomplicated patients had significantly lower costs (p<0.0001) compared to other groups. Patients with IHD had highest expenses 
(p<0.0001), followed by diabetic nephropathy (DN) and DF (p<0.0001). Cost incurred in diabetic neuropathy (DNeu) was almost the double compared 
to uncomplicated group, but annual medical cost (AMC) was minimum among other diabetic complications. DR had higher expenses compared to 
DNeu. The similar pattern of distribution was observed in other individual costs. A positive correlation was observed between the costs incurred 
and duration of diabetes, a negative correlation between the glycemic status and cost incurred. Cost incurred was double when compared to that of 
previous decade.
Conclusion: The total AMC is significantly higher in complicated diabetic patients as compared to those without complications. Diabetic patients with 
IHD had the highest expenses, followed by DN, DF, DR, and DNeu which was least expensive.
Keywords: Cost of illness, Direct medical cost, Complications, Type 2 diabetes mellitus.
INTRODUCTION
Diabetes mellitus (DM) is a disease that has significant economic 
impact on both for the patient and the health-care provider due to 
its chronicity and multiorgan Involment which results in frequent 
visit and admission to health facilities. High prevalence and higher 
rate of Complications endanger substantial negative implication on 
the economies. Costs involved in the management of diabetes can 
be classified into direct and indirect or intangible costs. Direct cost 
includes hospital services, including consultation charges, laboratory 
tests, and the daily management of DM, which includes the availability 
of products such as insulin, syringes, oral hypoglycemic agents, and 
blood glucose testing equipment which are known as pharmacy costs. 
Due to coexisting complications, patients may have hospital admissions 
and undergo various interventions/surgeries which enormously 
increase the direct costs. Transportation cost is known as direct 
non-medical cost. Costs range from relatively low-cost items, such as 
primary-care consultations and hospital outpatient episodes, to very 
high-cost items, such as long hospital inpatient stays for the treatment 
of complications [1]. Indirect cost includes loss of productivity due to 
sickness, absenteeism, disability, premature retirement, and premature 
mortality of the patients.
Due to these expenses, DM poses a great economic burden on the 
society which is of great concern.
Shobhana et al. reported a total annual cost of INR 4510 in a public 
sector hospital at Chennai in 1999, whereas the same author reports an 
annual cost of INR 15,596 in inpatients and INR 8578 in outpatients in 
an another study [2,3]. A cross-sectional study by Rao et al. reports cost 
for hospitalization INR 5925 in 2004 [4]. In 2005, three study reports 
are available to the best of our knowledge, among which cohort study 
in Northern India by Grover et al. reported a total cost of INR 4966.2 
over 6 months in patients with diabetes inclusive of consultations, 
investigations, nursing, and infrastructure. He also reported an indirect 
cost due to loss of wages was INR 2086.74, which also included drugs, 
food, and travel. [5]. However, small sample size was the limitation of the 
study. Kumar et al. reported a total direct cost of INR 6212.4, inclusive of 
tests, drugs, monitoring, etc., in his cohort study conducted in Delhi [6]. 
Ramachandran et al., in a cross-sectional study covering seven states in 
India, reported an annual direct cost of INR 8130 which included drugs, 
tests, hospitalization, surgery, and consultation [7]. A regional cohort 
study by Shivprakash et al. suggests a consultation charge of INR 363 [8]. 
In our previous report, we found that annual cost per diabetic person 
was INR 10,584, 19,326, and 25,960 for uncomplicated, complicated 
but not admitted, and complicated and admitted diabetics, respectively, 
in 2009 [9]. A study by Kumpatla et al. reports an annual expenditure 
of INR 4493 and 15280 with and without complications, respectively, 
in Chennai in 2009 [10]. A cross-sectional study from Maharashtra, by 
Kuchake et al. in 2010, reported a consultation cost of INR 116.85 and 
a Punjab-based study by Joshi et al. reported a consultation cost of INR 
166 [11,12].
In 2012, Hanamkonda-based cohort study by Akari et al. reported an 
annual direct cost of USD 314.15 in complicated diabetic patients and 
USD 29.91 in uncomplicated diabetic patients [13]. In a South India-
based randomized control trial by Abdi et al. reported a drug cost of 
USD 13.42 [14].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i11.27558
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There are various studies which tried to evaluate the economic burden 
due to DM, but each one of them has its own limitations due to lack of 
standardization of the methods used, improper documentation of data, 
lack of follow-up, etc. This study is an attempt to evaluate the economic 
burden of diabetes in a coastal district of Karnataka, India.
Objectives
To assess the annual medical cost (AMC) and consultation charges 
(direct medical costs) in uncomplicated hospitalized patients and annual 
health-care costs due to type 2 diabetes patients who are hospitalized 
due to various complications in coastal district of Karnataka, India.
Primary objectives are to:
1. Compare direct costs such as, AMC, annual laboratory cost (ALC), 
annual pharmacy cost (APC), annual consultation cost (ACC), annual 
hospital bed costs (AHBC), and annual surgical/intervention cost 
(ASC) in Type 2 DM (T2DM) patients, with and without complications
2. Compare AMC and other costs in diabetic patients with various 
complications
3. Find out correlation between cost incurred to the duration of diabetes





This study was a non-interventional retrospective study.
Study population
T2DM patients attending Justice K.S. Hegde Hospital, Nitte University, 
Mangalore, for at least 1 year.
Inclusion criteria
A total of 340 T2DM patients, 18–55 years of either gender will be 
included in the study. Patients attending the hospital services, with 
and without complications were included in the study. Patients with 
T2DM were identified by the American Diabetic Association guidelines 
2017. Diabetes complications and comorbidities were identified using 
ICD codes. Systematic sampling was conducted for 340 identified DM 
patients after obtaining permission from the Medical superintendent 
and Institutional Ethics Committee.
Exclusion criteria
Type 1 diabetic patients, gestational diabetes, and those with any 
other associated illnesses, other than diabetic complications, like liver 
disorders, etc., were excluded from the study.
Study period
Data were collected from the medical records of diabetic patients who 
obtained treatment between July 1, 2016 and June 31, 2017.
DATA COLLECTION
The non-interventional retrospective study was conducted in a 
multispecialty teaching hospital attached to K.S. Hegde Medical 
Academy, Nitte University, Mangalore. It caters tertiary health-care 
service to the coastal district of Karnataka state, India. The data of 
patients such as age, gender, duration of illness, complications of 
diabetes, number of hospital visits per annum for consultation and 
admission, glycated hemoglobin levels, AMC like APC, ACC, ALC, AHBC, 
and ASC of patients who have been receiving regular treatment for 
T2DM from July 2016 to June 2017 were collected from the hospital 
medical record department. Patients were classified into six groups, 
i.e., patients with no complications (uncomplicated cystitis) - Group I, 
patients with diabetic complication who were hospitalized during 1 year 
with different complications like diabetic retinopathy (DR) - Group II, 
diabetic nephropathy (DN) - Group III, diabetic foot (DF) - Group IV, 
diabetic neuropathy (DNeu) - Group V, and ischemic heart disease/
coronary vascular diseases (IHD) - Group VI. The AHBC, ALC, APC, ACC, 
ASC, and total annual cost medical cost (AMC) during hospitalization 
were calculated separately for each group. Data were collected from the 
hospital medical record section.
All costs were reported in INR. Data were collected from the Medical 
Record Department of Justice K.S. Hegde Medical Hospital, where 
patient records were fully computerized as per ICD classification.
Data analysis and interpretation
The data collected was scrutinized and coded before entering into the 
computer. The data were analyzed using the software SPSS version 16. 
The entered data was verified and checked for data errors during 
coding and data entry.
Statistical analysis
Descriptive statistics was used for calculating mean, standard error of 
mean, percentage, and median. Kruskal–Wallis test followed by post hoc 
test, and Dunn’s test was used to compare median costs between the 
groups as well as to compare costs in different groups based on duration 
of illness as well as complications. Spearman’s correlation test was used 
to find the correlation between duration of illness and direct medical 
cost as well as glycemic status and medical cost.
RESULTS
The patient characteristics were depicted in the Table 1. Total direct 
mean, median medical cost and percentage costs depicted in Table 2 
and Fig. 1. Comparison of mean and median costs in different groups are 
depicted in Tables 3 and 4. Post hoc test results depicting comparison 
of different groups in individual cost are depicted in Tables 5-10. 
Percentage contributions of these costs to AMC in Groups I–VI are 
depicted in Figs. 2-7.
A very highly significant differences (p<0.0001) in AMC, ALC, APC, ACC, 
AHBC, and ASC between all the groups (Table 2).
Uncomplicated patients (Gp I) had significantly lower costs (p<0.0001) 
compared to other groups. Patients with IHD (Gp VI) had highest 
expenses (p<0.0001), followed by DN (Gp III) and DF (Gp II) (p<0.0001). 
Cost incurred in DNeu (Gp V) was almost the double compared to 
uncomplicated group, but AMC was minimum among other diabetic 
complications. DR (Gp II) had higher expenses compared to DNeu 
(Gp V) (Table 4). The similar pattern of distribution was observed in 
other individual costs.
When we consider total direct medical cost, cost due to surgery/
intervention contributed to 65%, laboratory charges 14%, pharmacy 
and medications 12%, bed charges due to hospital admissions 6%, and 
consultation charges 3% (Fig. 4).
On analyzing different costs in all the six groups, it was found that 
surgical/interventional costs contribute to 59%–69% of total direct 
medical costs, ALC to 12%–19%, APC made up to 9%–15%, ACC 
contributed to 3%–5%, and AHBC accounted for 4%–6% of annual 
direct medical cost (AMC) (Figs. 2-7).
A positive correlation was observed between duration of complications 
and cost incurred (r=0.743, p<0.001).There was a negative correlation 
between the glycemic status and cost incurred (r=−0.604, p<0.001).
POST HOC TEST RESULTS
 Depicted in Tables 5-10
DISCUSSION
A very highly statistically significant differences (p<0.0001) were 
observed in AMC, ALC, APC, ACC, AHBC, and ASC between all the 
groups (Table 2). Uncomplicated patients (Group I) had significantly 
lower costs (p<0.0001) compared to other groups. Patients with IHD 
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(Group VI) had highest expenses (p<0.0001), followed by DN (Group III) 
and DF (Group II) (p<0.0001). Cost incurred in DNeu (Group V) was 
almost the double compared to uncomplicated group, but AMC was 
minimum among other diabetic complications. DR (Gp II) had higher 
expenses compared to DNeu (Group V) (Table 4). The similar pattern of 
distribution was observed in other individual costs.
It is evident from our study that direct health-care costs for treating 
diabetes and its complications are on the rise. The study revealed 
that the average cost of treating and managing diabetes-related IHD 
complications (Group VI) was the highest among all other complications. 
AMC was 7.2 times higher as compared to that in uncomplicated 
Group I. This increase in AMC is due to corresponding rise in laboratory 
charges (5.4 times), pharmacy charges (9.4 times), consultation charges 
(3.1 times), and hospital bed charges (4 times) due to probable increase 
in frequency and duration of admissions, higher surgical/intervention 
charges (7.4 times).
The maximum contribution is from medical appointments, tests, 
outpatient catheterization procedures, medications in use, and 
transport of the patient to the hospital, etc. In addition to hypoglycemic 
drugs, cardiologists prescriptions might contribute significantly to 
APC. We assumed that the drugs were purchased by the patients at 
pharmacies using their own resources without government subsidies 
and were taken with 100% treatment adherence. Additional laboratory 
tests to monitor cardiac functions and lipid profiles contributed to 
ALC. Cardiac and imaging tests included were myocardial scintigraphy 
(stress and resting), Echocardiography (stress and  resting) exercise 
test, Holter, ambulatory blood pressure monitoring (ABPM), chest X-ray, 
carotid and vertebral Doppler echocardiography, venous color Doppler 
echocardiography, and chest tomography make major contribution 
to investigations. Hospital treatment consists of hospitalization days, 
Intensive Care Unit days, laboratory and diagnostic tests, angioplasty 
procedures with or without stent implantation, cardiac catheterization, 
and coronary artery bypass surgery performed during hospitalization 
made a huge contribution to ASC or intervention costs. Our results are 
supported by a recent Brazilian study by Schlatter et al., which showed 
that the direct costs of longitudinal IHD treatment were high and were 
primarily driven by chronic pharmacological treatment and days of 
hospitalization and interventions [15].
DN (Group III) was the second highest expensive complication of 
diabetes. AMC, ALC, APC, ACC, AHBC, and ASC were higher by 4.6, 3.3, 
5.9, 3.4, 2.7, and 4.6 times, respectively, compared to uncomplicated 
group. Higher cost incurred might be due to frequent investigations, 
consultations, and drugs. A recent study by Jose et al., focused on 
pharmacoeconomic aspects of DN from India, reported that monthly 
cost of dialysis contributed most (37%) to the total cost in DN 
patients [16]. An earlier study from India reported that cost per dialysis 
in India ranged from INR 150 in government hospitals to INR 2000 in 
private hospitals [17]. In most of the private hospitals, the average cost 
of dialysis per patient per month was INR 12,000 and the yearly cost is 
INR 140,000 equivalent of USD 3000, and this is in sharp contrast to the 
annual cost of USD 60,000 in the United States and the United Kingdom. 
In the study by Jose et al., monthly average cost of dialysis per patient 
was INR 9060 [16]. The patients on an average underwent eight 
dialysis sessions per month in the study which was comparable with 
a study by Satyavani et al. done in a South Indian state [18]. This was 
not affordable to many patients as around 89% belonged to lower 
to middle-class socioeconomic strata in the study [16]. In a study by 
Satyavani et al., the cost for a person on hemodialysis was 4 times 
higher than for persons with chronic kidney disease (CKD) only (INR 
61,170 vs. 12,664) [18]. A study by O’Brien et al. in Canada showed 
that early stage complications (e.g., microalbuminuria: USD 62 event 
cost; USD 10 state cost) had relatively low financial burden compared 
to more costly advanced stages (e.g., end-stage renal disease [ESRD], 
USD 63,045 state cost) [19]. Kidney transplantation remains the 
most cost-effective treatment for ESRD, offering considerable savings 
and improvement in the quality of life in these patientsas shown in a 
study by Satyavani et al. [18,20]. The total median cost of treatment of 
diabetic patients with ESRD was very high (on average INR 500,000) 
compared with transplant patient (INR 345,000) over a period of 
2 years, whereas the average cost of treatment of diabetes with and 
without CKD was INR 100,000 and INR 30,000, respectively [21]. Strict 
glycemic and blood pressure control can reduce the incidence and slow 
the progression of DN [22]. Improvement in diabetes control, early 
diagnosis of DN, and treatment has the potential to reduce the direct 
cost involved in treatment of DN [21].
Our results are supported by the study by Kumpatla et al. who 
reported that total expenditure for treating renal, cardiovascular, and 
retinal complications was more or less similar among type 2 diabetic 
patients [10]. Satyavani et al. studied the direct cost of treating 
CKD in type 2 wdiabetic patients in India. The authors assessed the 
Table 1: Demographic profile with glycemic parameters
Characteristics Patient characteristics 
Gender Male:Female - 60:40
Mean age in years 58.96±2.56
Duration of disease in years 8.41±1.09
Hb1Ac (%) 7.69±0.11
Hb1Ac: Glycated hemoglobin
Table 2: Annual mean and median costs in T2DM








T2DM: Type 2 diabetes mellitus, ATC: Annual transportation cost, 
SEM: Standard error of mean, AMC: Annual medical cost, ALC: Annual 
laboratory cost, APC: Annual pharmacy cost, ACC: Annual consultation cost, 
AHBC: Annual hospital bed costs, ASC: Annual surgical cost
Table 3: Mean costs incurred in uncomplicated and complicated DM












AMC 14230±1564.6 23643±3223.4 39374±4141.1 39520±5010.1 25021±3802.2 61769±5560.6
ALC 3369.3±307.3 6296.9±1086.3 7032.1±1081.1 7537.2±1293.6 5221.8±844.02 9601.9±780.91
APC 1651.3±259.77 4013.3±676.4 6433.6±1119.5 8884.3±2331.7 3893.8±685.5 8328.8±912.5
ACC 826.5±78.7 1686.9±485.5 1767.4±248 1752.6±224.9 1483±278.1 2799.1±333.25
AHBC 1150.6±154.54 1631±522.44 1883.9±296.51 2692±685.29 1354.2±220.46 3274.2±483.38
ASC 11652±136.21 19900±2764.9 28237±2865.1 37189±4909.2 21437±3429.9 53724±4910.2
AMC: Annual medical cost, ALC: Annual laboratory cost, APC: Annual pharmacy cost, ACC: Annual consultation cost, AHBC: Annual hospital bed costs, ASC: Annual 
surgical cost, DM: Diabetes mellitus, UC: Uncomplicated cystitis, DR: Diabetic retinopathy, DN: Diabetic nephropathy, DF: Diabetic foot, DNeu: Diabetic neuropathy, IHD: 
Ischemic heart disease
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comparative cost of treatment of diabetic patients without CKD, 
those with Stage 1-4 CKD, who needs dialysis, and those with kidney 
transplantation [18]. They determined cost of treatment at two levels: 
Cost of hospitalization and total cost of treatment over the previous 
2 years taking into account costs of hospitalization, consultation, 
medication, laboratory tests, dialysis treatment, transplantation 
surgery, and transportation. Ramachandran and Jha demonstrated 
that even kidney transplantation, the most cost-effective form of renal 
replacement therapy, in a public sector hospital can have catastrophic 
financial consequences pushing the majority of families into severe 
poverty [23].
DKD is preventable. There is substantial evidence that early and 
effective therapeutic intervention in type 2 diabetes can prevent DKD 
and retard the progression of established DKD.
DF (Group IV) was the next costliest complication. AMC, ALC, APC, 
ACC, AHBC, and ASC were higher by 4, 3.5, 6.1, 3.6, 2.8, and 4.8 times 
compared to uncomplicated group.
Some studies have shown 15% of diabetic patients will be suffering from 
DF ulcer during their lifetime [24]. DF ulcer is the most general cause of 
hospitalization in diabetic patients [25]. Lower extremity amputation 
is associated with prolonged hospitalization and rehabilitation and 
also required home care and social support which contribute to the 
economic burden [26]. It should be considered that the burden of DF-
related neuropathy is two folds than the burden of DR or nephropathy 
currently.
85% of DF amputations are preventable with appropriate care and 
education. Ideal management for prevention and treatment of DF is as 
follow: Regular perception of foot, determine at-risk foot, education to 
patient and health staff, appropriate foot coverage, and early treatment 
of foot problems [27].
DR (Group II) was in fourth place to contribute to the health-care cost 
among the complications of DM. AMC, ALC, APC, ACC, AHBC, and ASC 
were 2.3, 2, 3.4, 2.4, 1.4, and 2.3 times, respectively, higher compared 
to uncomplicated group. The increased cost could be attributed to 
screening, retinography, treatment costs, antivascular endothelial 
growth factor drugs, etc. There are hardly many studies done in this area 
in Indian settings. Average health-care costs increase considerably with 
the severity of retinopathy, which suggests that preventing progression 
of DR may lower health-care cost.
Fig. 2: Percentage of various costs in uncomplicated type 2 
diabetes mellitus
Fig. 1: Percentage distribution of medical costs of type 2 diabetes 
mellitus patients
Fig. 3: Percentage of various costs in diabetic retinopathy
Fig. 4: Percentage of various costs in diabetic nephropathy
Fig. 5: Percentage of various costs in Douglas fur
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DNeu (Group V) had minimum expenses among the complications of 
diabetes, but AMC, ALC, APC, ACC, AHBC, and ASC of this group were 
2, 1.6, 2.6, 1.9, 1.1, and 1.9 times higher, respectively, than those in 
uncomplicated group.
As expected, the group without any complications, had reduced cost 
pattern for all the parameters, which is evident that high costs for 
diabetes care are not just due to the disease but due to its associated 
complications. Our reports are supported by a recent study by Leelavathi 
et al. carried out in the same geographical area [28]. According to 
the study, average cost per diabetic patients without complications 
is Rs. 917.73 compared to the diabetic patients with complications 
Rs. 1448.51 per month. Annual cost of medication was found to be 
1.6 times higher for diabetes with complication compared to those 
without complications. Cost-of-illness (COI) for DM with complication 
was reported to be 1.4 times higher than those without complications. 
Those patients who undergo dialysis in addition to the complications 
spend 7.3 times higher than those without complications. Patients 
who undergo cardiology intervention along with complications spend 
7.4 times higher than patients who do not have complications. It also 
reports that hospitalization charge was 1.2 times higher for DM with 
complications. As per this study, cost per DM patient on dialysis (usually 
2 times per week) is Rs. 97,920.00 per annum. Cost per diabetic patient 
undergoing cardiac intervention is Rs. 72,120.00 per intervention. It 
showed that annual cost of treatment for those who were on dialysis was 
6.8 times higher and annual cost of treatment for cardiac intervention 
















AMC 7750 17587.5 35875 30980 15237.5 55450 <0.0001
ALC 1919.8 3758.5 6405 6695 3016.05 10462.3 <0.0001
APC 936.5 3161.9 5540 5758 2418.65 8801.6 <0.0001
ACC 490 1154.8 1667.2 1765 915.5 1535 <0.0001
AHBC 552 784.6 1514.4 1569 614.4 2183.9 <0.001
ASC 6631 14936.4 30402.5 31631 12743.65 48860 <0.0001
DM: Diabetes mellitus, UC: Uncomplicated cystitis, DR: Diabetic retinopathy, DN: Diabetic nephropathy, DF: Diabetic foot, DNeu: Diabetic neuropathy, IHD: Ischemic 
heart disease, AMC: Annual medical cost, ALC: Annual laboratory cost, APC: Annual pharmacy cost, ACC: Annual consultation cost, AHBC: Annual hospital bed costs, 
ASC: Annual surgical cost
Table 5: Comparison of AMC in different groups
Groups p value
I vs. III <0.0001
I vs. IV 0.001
I vs. VI <0.0001
II vs. VI <0.0001
III vs. VI 0.001
IV vs. VI 0.014
V vs. VI <0.0001
AMC: Annual medical cost
Table 6: Comparison of ALC in different groups
Groups p value
I vs. III 0.003
I vs. IV 0.013
I vs. VI <0.0001
V vs. VI <0.0001
ALC: Annual laboratory cost
Table 7: Comparison of APC in different groups
Groups p value
I vs. III <0.0001
I vs. IV <0.0001
I vs. VI <0.0001
II vs. IV 0.028
II vs. VI 0.008
IV vs. V 0.010
V vs. VI 0.001
APC: Annual pharmacy cost
Table 8: Comparison of ASC in different groups
Groups p value
I vs. III 0.004
I vs. IV <0.0001
I vs. VI <0.0001
II vs. VI <0.0001
III vs. VI <0.0001
V vs. VI <0.0001
ASC: Annual surgical cost
Fig. 7: Percentage of various costs in ischemic heart disease
Fig. 6: Percentage of various costs in diabetic neuropathy
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was 5 times higher than patients who did not have any intervention. 
Moreover, there may not be much difference in the cost of investigations, 
consultation cost, transportation, and indirect cost involved in 
diabetic care. They found that total COI for diabetic care without any 
complication was Rs. 22,456.97/- per patient per annum. Median of 
total COI for diabetic care with complication was Rs. 30,634.45/- per 
patient per annum, it was 1.4 times higher, median of COI for diabetic 
care with complication plus dialysis was Rs. 164,211.40/- per patient 
per annum, it is 7.3 times higher and the median COI for diabetic care 
with complication plus cardiac intervention was Rs. 166,785.85/- per 
patient per annum which is 7.4 times higher and statistically significant 
difference observed between these groups. A similar study conducted 
by Metgud showed that cost of outpatient care for diabetic patient with 
chronic renal failure (CRF) requiring dialysis was 15 times higher than 
the cost of outpatient care for a diabetic patient without CRF (excluding 
dialysis cost) [29].
Compared to our study, costs mentioned in the above study were more. 
We cannot arrive at any conclusion by comparing numbers, as the costs 
are different in different settings. Even though cost variations exist, in 
general, we can conclude that diabetes poses economic burden which is 
amplified several times when associated complications.
The studies have reported the cost of managing diabetic patients with 
or without microvascular and macrovascular complications. Patients 
with microvascular complications had higher the cost of management, 
and those with macrovasular complications had even higher cost of 
management. Difference in the cost and proportions in different studies 
may be due to the period of study, place, method of collecting the data, 
and economic values. However, all the studies have concluded that 
diabetes is a disease associated with significant economic burden and 
diabetes complication make it more expensive. It is not only a burden to 
the patient, his family but also to the nation.
Our results support well-established fact that complications get worsen 
with longer duration of diabetes. Our study is in accordance with a 
report by Leelavathi et al. [28]. According to this study, regarding the 
duration of diabetes in the study population, 60.8% diabetic patients in 
without complication group had <5 years of history of diabetes, whereas 
in diabetes with complication group, 64.6% of diabetic patients had 
above 5 years of history of disease.
The total expenditure correlated significantly with age and duration of 
diabetes. The expenditure involved in treating long-term complications 
was significantly associated with duration of diabetes and presence of 
complications in the current study.
The duration of stay in the hospital, number of visits made for post-
surgical dressings, hospital charges, laboratory charges, and medical 
consultations are the factors which significantly contribute to the 
increased cost in DF. The duration of hospital stay which is substantially 
longer in patients with foot complications increase the cost. Such 
information on hospital stay days and costs may help to emphasize 
earlier intervention and prevention of complications of diabetes.
The cost of diabetes can be a major burden as the disease does not have 
cure, and its complications increase with increasing duration of the 
disease. This was seen in a study by Chandra et al., a positive correlation 
of increasing cost with duration of diabetes [30].
Factors such as education and socioeconomic condition of the patient 
do contribute the cost in case of diabetes. It has been documented 
that urban people spend more money on diabetes compared to rural 
counterpart not only due to better awareness but also due to greater 
affordability [31].
A study by Hussain et al. suggested that the requirement of resources 
could be minimized by better care, treatment, and understanding of 
the disease [32]. Anandayani et al. suggested that intensified glycemic 
control is important in reducing complications and also to improve the 
quality of life in diabetic patients [33].
Limitations of the study
There are a few limitations in our study design. It is important to note 
that the data collected is from medical college teaching hospitals and 
the generalizability of results may be limited to certain private health-
care centers, the projected cost estimates were mainly based on urban 
patients whose pattern of disease may be different compared to rural 
patients. We could not assess the indirect cost and the cost of care for 
structured and comprehensive assessment of disability in this study. 
Educational and other socioeconomic details of patients could not be 
accessed as it was a hospital based study.
CONCLUSION
DM is a disease with significant financial burden which imposes an 
economic burden. The total AMC is significantly higher in complicated 
diabetic patients as compared to those without complications. Diabetic 
patients with IHD had the highest expenses, followed by DN, DF, DR, and 
DNeu which was least expensive. Positive correlation between duration 
of diabetes and cost incurred and negative correlation of glycemic control 
and cost incurred, suggest a need for strategies that aim at reducing 
the escalating cost burden by achieving targeted glycemic control, 
prompt and effective management of complications, and operationalize 
regular and early screening for complications. Awareness creation on 
primary and secondary prevention of diabetes and its complications is 
the need of the hour, alongside capacity strengthening of medical and 
paramedical professionals involved in diabetes care.
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